COMBIPACK PREPIT 80/125 CAP

About

Combipack Prepit typically contains aprepitant, an antiemetic agent that selectively blocks substance P/neurokinin 1 (NK1) receptors. These receptors are involved in the emetic reflex, and their blockade helps prevent both acute and delayed chemotherapy-induced nausea and vomiting (CINV). This combipack is designed to provide a multi-day regimen, often with varying doses, to ensure sustained antiemetic protection during and after highly emetogenic chemotherapy.

Aprepitant is usually administered as part of a combination regimen with a corticosteroid (e.g., dexamethasone) and a 5-HT3 receptor antagonist (e.g., ondansetron) to achieve optimal CINV prophylaxis. Its unique mechanism of action complements other antiemetics, making it a cornerstone in managing one of the most distressing side effects of cancer treatment. The specific dosing in a combipack ensures patient adherence to the complex multi-day regimen.

Uses

• Prevention of acute CINV
• Prevention of delayed CINV
• Highly emetogenic chemotherapy
• Moderately emetogenic chemotherapy

Directions For Use

Take orally as directed by your physician, usually before and after chemotherapy, with or without food.

Benefits

• Highly effective CINV prevention
• Covers both acute and delayed phases
• Improves patient comfort during chemotherapy
• Reduces need for rescue antiemetics
• Enhances overall quality of life
• Synergistic with other antiemetics

Side Effects

• Fatigue and asthenia
• Hiccups
• Constipation
• Diarrhea
• Headache
• Dizziness
• Dyspepsia
• Abdominal pain
• Anorexia
• Neutropenia
• Elevated liver enzymes
• Rash

Safety Measures

• Alcohol - Limit or avoid alcohol consumption as it may exacerbate gastrointestinal side effects like nausea or dyspepsia.
• Pregnancy - Use only if clearly needed and potential benefits outweigh risks; consult a physician before use.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if aprepitant is excreted in human milk.
• Liver - Use with caution in patients with severe hepatic impairment; monitor for adverse reactions.
• Kidney - No dose adjustment is generally needed for patients with renal impairment.
• Lung - No specific lung-related safety concerns are typically associated with aprepitant.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.